Trisomy 21 and Immune Dysregulation: Bridging Research and Clinicial Practice

Moderator(s)

• PL

  Pui Lee, MD, PhD

  Boston Children's Hospital
  Newton, Massachusetts, United States

  Disclosure(s): Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 31, 2025)
• DI

  Daniel Ibanez, MD

  Inova Children's Hospital
  Washington, District of Columbia, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

Session Coordinator(s)

• PL

  Pui Lee, MD, PhD

  Boston Children's Hospital
  Newton, Massachusetts, United States

  Disclosure(s): Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 31, 2025)

Individuals with trisomy 21 have increased susceptibility to infections, malignancies, and autoimmune diseases. Recent immune profiling studies have shown that trisomy 21 is associated with significant derangement of both innate and adaptive arms of the immune system. This session will review recent advances in understanding the immune dysregulation associated with trisomy 21. Pharmacologic approaches to correct the underlying immune abnormalities in patients with trisomy 21 will be highlighted.

Presentations:

• 10:30 AM – 11:00 AM Central Time

  Defining the Immune Landscape Associated with Trisomy 21
  

  Speaker: Dusan Bogunovic, PhD – Columbia University Medical Center
• 11:00 AM – 11:30 AM Central Time

  Modulating the Immune System in the Clinical Care of Down's Syndrome
  

  Speaker: Jessica Bloom, MD, MS – University of Colorado